Hiroshi Yatsuhashi
Overview
Explore the profile of Hiroshi Yatsuhashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
3231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naganuma A, Makita F, Sugimoto R, Kikuchi M, Furuta K, Iwamoto S, et al.
Clin Nutr ESPEN
. 2024 Dec;
65():357-364.
PMID: 39675424
Introduction: Hand-foot-skin reaction (HFSR) is the most common side effect of multi-tyrosine kinase inhibitor therapy for unresectable hepatocellular carcinoma (uHCC). Sarcopenia has been reported to be a poor prognostic factor...
2.
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Ido A, et al.
Hepatol Res
. 2024 Oct;
PMID: 39470448
Aim: The incidence of and factors involved in gastroesophageal varix-related events in hepatitis C virus-related cirrhosis patients, including decompensated cirrhosis, after direct-acting antiviral therapy are unclear. Methods: We conducted a...
3.
Yoshida S, Koga T, Fujita Y, Yatsuhashi H, Matsumoto H, Sumichika Y, et al.
Front Immunol
. 2024 May;
15:1385654.
PMID: 38711500
Background: Autoinflammation with cytokine dysregulation may be implicated in the pathophysiology of adult-onset Still's disease (AOSD); however, the relationship between galectins and cytokines in patients with active AOSD remains unknown....
4.
Hitomi Y, Ueno K, Aiba Y, Nishida N, Kono M, Sugihara M, et al.
Hepatology
. 2024 Apr;
80(4):776-790.
PMID: 38652555
Background And Aims: Previous genome-wide association studies (GWAS) have indicated the involvement of shared (population-nonspecific) and nonshared (population-specific) susceptibility genes in the pathogenesis of primary biliary cholangitis (PBC) among European...
5.
Uojima H, Yamasaki K, Sugiyama M, Kage M, Ishii N, Shirabe K, et al.
J Gastroenterol
. 2024 Apr;
59(7):598-608.
PMID: 38625546
Background: The relationship between liver fibrosis and inflammation and Mac-2-binding protein glycosylation isomer (M2BPGi) in patients with chronic liver disease (CLD) other than hepatitis C remains uncertain, owing to the...
6.
Abiru S, Kugiyama Y, Suehiro T, Motoyoshi Y, Saeki A, Nagaoka S, et al.
J Clin Biochem Nutr
. 2024 Mar;
74(2):162-168.
PMID: 38510683
Zinc deficiency occurs in a variety of diseases, including chronic liver disease (CLD). We investigated the correlation between zinc levels and biochemical and hematological tests in CLD and the effect...
7.
Yamana H, Yamasaki K, Jo T, Yatsuhashi H, Yasunaga H
Ann Clin Epidemiol
. 2024 Mar;
5(4):107-112.
PMID: 38504953
No abstract available.
8.
Toumi M, Wallace J, Cohen C, Marshall C, Kitchen H, Macey J, et al.
BMC Public Health
. 2024 Feb;
24(1):611.
PMID: 38408941
Background: People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma and a functional cure on stigma. Methods: Adults...
9.
Fung S, Pan C, Wong G, Seto W, Ahn S, Chen C, et al.
Aliment Pharmacol Ther
. 2023 Oct;
59(2):217-229.
PMID: 37905449
Background: Patients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles. Aim: To evaluate how these changes affect...
10.
Tahata Y, Hikita H, Mochida S, Enomoto N, Ido A, Kuroda H, et al.
J Gastroenterol
. 2023 Oct;
58(12):1211-1221.
PMID: 37831182
Background: The prognosis of cirrhosis is clearly stratified by liver function. Although direct-acting antiviral (DAA) has recently been used to eliminate hepatitis C virus (HCV), it is not clear whether...